When Donald Trump is sworn in as president there are questions as to what may happen to various agencies in the nation’s capital, especially the U.S. Food and Drug Administration. There are some concerns that the Trump administration may look to dismantle the regulatory agency.
Shire continues to expand its presence in booming Kendall Square. The company announced it will establish a rare disease innovation hub that will include the leasing of 343,000 square feet of a former Genzyme property – which is adjacent to current Shire property.
The National Institute for Clinical Excellence has finally given backing for the NHS’ approval of Perjeta for human epidermal growth factor receptor 2-positive breast cancer.
If “some” data helps life sciences firms develop insights to improve their businesses, having access to Big Data from multiple sources should lead to many more and much better insights. But more often than not, access to more data is having the opposite effect.
U.S. officials have given a green light for two clinical trials testing AstraZeneca’s cancer immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding.
Intarcia Therapeutics Inc. submitted a marketing application for its matchstick-size implantable drug-delivery pump for diabetes to the U.S. FDA.
Some families gathering for Thanksgiving this week may have something to argue about besides politics: what to do when teens at the table follow a different diet than everyone else.
More than 18 million people now have access to life-saving AIDS treatment, 1.2 million more than at the end of last year, the United Nations said.
Theranos has failed to turn its dream of a blood-testing and miniaturized laboratory technology into any kind of commercial or regulatory success and the company is facing a myriad of lawsuits – bad news that has dropped its estimated value of $9 billion to a few hundred million at best.
Following the release of disappointing Phase II data, shares of Acorda Therapeutics were dropping after the company announced plans to discontinue development of dalfampridine for the treatment of post-stroke walking difficulties (PSWD).